6 results
To evaluate the safety and performance of the BackBeat Moderato system.
The primary objective of this study is to assess the efficacy of pridopidine 67.5 to 112.5 mg twice daily (bid) on motor impairment in patients with HD after 26 weeks of treatment using the Unified Huntington*s Disease Rating Scale (UHDRS) Total…
To evaluate the safety and effectiveness of the BackBeat Moderato system.
Primary Objective: The primary objective of this study is to evaluate safety and tolerability of pridopidine in patients with HD.Secondary Objectives: The secondary objectives of the study are to assess the effects of long-term, open-label dosing…
The purpose of this Phase 3 study is to further evaluate the effect of pridopidine 45*mg BID on functional capacity, as well as motor and behavioral features of HD in early-stage participants (TFC*713).
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - A Prospective Multicenter Study.
To evaluate the safety of IMPEDE-FX Embolization Plug and/or IMPEDE-FX RapidFill to fill a AAA sac outside of an EVAR stent graft, and the efficacy of the IMPEDE-FX Embolization Plugs to reduce the volume and/or diameter of the AAA sac and/or the…